Author: Deepbio
[Posters] AACR 2023 – Clonal Evaluation of ERG/SPINK1 Status to Determine Disease Progression Using Whole Mount Prostatectomy Specimens
Deep Bio’s Novel Study Results Reaffirm Its Global Presence
USCAP 2023 is Deep Bio’s sixth consecutive year of presenting research abstracts
SEOUL, SOUTH KOREA (PRWEB) MARCH 14, 2023 – Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software shared three research abstracts at the United States and Canadian Academy of Pathology (USCAP) 2023 which is being held in New Orleans from March 11th to 16th.
The abstracts explore deep learning-based analysis of prostate cancer, Deep Bio’s main focus area, and c-MET measurements in lung cancer. In particular, collaborative research with ARUP, one of the top CLIA labs in the US, for the validation of a deep learning algorithm for prostate cancer detection and Gleason grading was presented at a platform session.
Other two presentations about the c-MET research:
- evaluation of attention-based tumor area segmentation deep learning models for c-MET immunohistochemical stained non-small cell lung cancer slide images, and
- Comparative analysis of c-MET expression using image analysis model in IHC stained WSIs were introduced during poster sessions.
Deep Bio is also participating in this year’s American Association for Cancer Research (AACR) and American Urology Association (AUA) in April. AACR has accepted two research abstracts this year about molecular subtype prediction in breast cancer using deep learning and molecular mapping in prostate cancer.
“It is inspiring that Deep Bio is presenting not only our own study but collaborative research abstract with reputable US CLIA laboratory ARUP at renowned international conferences,” said Sun-Woo Kim, CEO of Deep Bio. “As demand for precise diagnosis keeps increasing in the era of personalized cancer treatment, we will strive to bring differentiated deep learning technologies that can be utilized for multiple cancer types and biomarkers in addition to prostate and breast cancers, which are our focus areas and lead digital cancer pathology both in Korean and global markets” added he.
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.kr
[Posters] USCAP 2023 – Evaluation of Attention-based Tumor Area Segmentation Deep Learning Models for c-MET Immunohistochemical Stained Non-small Cell Lung Cancer Slide Images
[Posters] USCAP 2023 – Comparative Analysis of c-MET Expression Using Image Analysis Model in IHC Stained WSIs
Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Cancer Solution with a Leading Digital Pathology Platform
Pathologists can now have access to the state-of-the-art AI prostate cancer grading solution
SEOUL, SOUTH KOREA (PRWEB) NOVEMBER 15, 2022 – Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the latest AI-powered prostate cancer solution.
AI-powered cancer diagnostics has been proving its utility not only in research, but increasingly in supporting and improving pathologists’ decisions, workflow efficiency, and diagnostic precision. Deep Bio’s deep learning-based CE-IVDD prostate cancer diagnosis support software, DeepDx® Prostate, empowers pathologists by identifying cancerous areas and grading their severity providing a Gleason scoring.
With this collaboration, DeepDx® strengthens Visiopharm’s diagnostic offering to its European diagnostic customers. This application expands pathologists’ accessibility to the latest cutting-edge H&E-based AI solutions for prostate cancer, which today is a large diagnostic indication that is both time and labor-intensive in diagnostic pathology labs. With its extensive AI-based image analysis solutions for multiple cancer types, Visiopharm’s platform is contributing to the global adoption of digital pathology and AI.
The first phase of integration of DeepDx® into Visiopharm’s digital pathology platform has been completed. In the next phases, Visiopharm will together with Deep Bio scale up the solution as interest grows. The two companies plan to add additional AI cancer pathology solutions over time for prostate and breast, among others.
“Digital transformation in healthcare is not a new concept anymore. Pathology, which has been slow to undergo digital transformation, is fast becoming digitalized due to a diverse range of AI solutions now available for implementation and validation”, said Sun Woo Kim, the CEO of Deep Bio. “Our dedication to AI for digital pathology has taken a major step forward with this collaboration and we are pleased to offer our latest technology to more labs and hospitals across the world through this opportunity. We will continue to support medical professionals to optimize their decisions which ultimately lead to the best patient care,” he added.
The second phase of integration will aim for tighter interoperability among the platform and AI solutions, helping both companies to better promote and distribute to healthcare institutions around the world.
Michael Grunkin, CEO of Visiopharm said, “We are seeing a lot of demand for this particular application among both our clinical research- and diagnostic customers and partners. In diagnostic workflows, this APP has the potential to support pathologists in automating time-consuming and repetitive work, while improving turn-around-time and standardization. This partnership with Deep Bio is a good example of how our scanner, LIMS, and PACS agnostic platform allow our users to benefit both from our own apps and best-in-class apps from our growing partner network, to gain access to a full diagnostic menu.”
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit www.deepbio.co.kr.
About Visiopharm
Visiopharm® is a world leader in AI-driven precision pathology software. Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With highly advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows. Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 780 user accounts and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, Netherlands, and the United States.
Deep Bio Inc. successfully integrates DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs.
Discover how Deep Bio Inc. (딥바이오) successfully integrates their DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs.
Read the exciting new case study!
Deep Bio Acquires ISO 27001 Certification for an Information Security Management System
Enhanced security and reliability through adherence to globally recognized information security standards
SEOUL, SOUTH KOREA (PRWEB) OCTOBER 27, 2022 – Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has acquired ISO/IEC 27001:2013 certification, the international information security management system standards.
ISO/IEC 27001:2013 specifies the requirements for establishing, implementing, maintaining, and improving an information security management system and provides a risk management process so that organizations can accordingly keep their information safe. As the most widely-recognized certification for information security management, it strictly evaluates 144 criteria in 14 categories such as information security policy, security processes, security controls and services. By obtaining the certification, Deep Bio has demonstrated its commitment to protecting data through systematic management for information security.
“As we handle a myriad of medical data which require a more secure approach, we are very aware of the importance of information security above all else, and make every effort to build a thorough security management system,” said Sun Woo Kim, the CEO of Deep Bio. “Achieving the certification proves our robust data security management systems. We will keep renewing this certification so that our partners and customers can use our AI-based cancer diagnostic support software with confidence,” he mentioned.
Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, is leading the digital transformation in pathology with Korea’s first approved AI-based cancer diagnostic support software DeepDx®-Prostate and AI-based prostate cancer severity-grading software DeepDx®-Prostate Pro. More importantly, the company plans to execute purchase agreements with five Korean hospitals for DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS).
Deep Bio also continues to build its global presence through overseas partnerships with digital pathology platform providers in the US, Europe, and India, as well as conduct research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US. The company also has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, among others.
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit www.deepbio.co.kr.
Deep Bio Selected as ‘Korea AI Startup 100’ for Two Consecutive Years
AI experts expect Deep Bio to succeed in the healthcare industry with its innovative technology
SEOUL, SOUTH KOREA (PRWEB) OCTOBER 21, 2022 – Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has been selected as one of the promising AI startups in the ‘Korea AI Startup 100’ list for the second time in a row.
‘Korea AI Startup 100’, an annual accelerator project cohosted by the Korea Economic Daily and AI One Team, an Industry-University-Research Council, discovers promising Korean AI startups. The project aims to support companies to strengthen their market presence and build their capability, thus enhancing national AI competitiveness in the global market as well as boosting the establishment of the startup ecosystem.
To choose the most notable 100 startups, a committee made up of AI experts evaluated candidates based on criteria that the Korea Advanced Institute of Science and Technology (KAIST) and KT Economics & Management Research Institute developed. The applicants were assessed on both quantitative factors such as market growth potential, corporate value, competitiveness in the AI technology space, and qualitative aspects including corporate sustainability.
After three rounds of evaluation, Deep Bio was selected as one of the finalists of the Korea AI Startup 100 in the healthcare industry. “It is a great honor to be designated as a promising startup that represents Korea. This opportunity once again becomes motivation for our company to advance our AI capability that can contribute to the society,” said Sun Woo Kim, the CEO of Deep Bio. He also added, “with our innovative deep learning technology, we will strive to lead the digitalization of medical care.”
Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, is leading the digital transformation in pathology with Korea’s first approved AI-based cancer diagnostic support software DeepDx®-Prostate and AI-based prostate cancer severity-grading software DeepDx®-Prostate Pro. More importantly, the company plans to execute l purchase agreements with five Korean hospitals for DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS).
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit www.deepbio.co.kr.
Deep Bio Welcomes New Advisors to Accelerate Its Growth in Global Market
The new advisors will focus on Deep Bio’s overseas business expansion as well as strengthening its expertise in cancer pathology.
SEOUL, SOUTH KOREA (PRWEB) OCTOBER 10, 2022 – Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has appointed professionals in pathology and precision medicine as advisors to reinforce its cancer pathology expertise and accelerate its overseas business growth.
This month, a pathologist Dr. Michael Bonham (MD, Ph.D.) joined Deep Bio as a new advisor. With renowned expertise in both pathology and med-tech innovations, Dr. Bonham is expected to provide valuable insights and support for the company’s strategic partnerships and R&D with other digital pathology companies as well as research institutes. Before joining Deep Bio, he built up extensive experience working at many renowned bio companies and pathology laboratories including Genomic Health. In particular, as a former Chief Medical Officer (CMO) of Proscia, a US digital pathology platform provider, he led the success in the development and marketing of AI-based cancer diagnosis support solutions and platforms.
“I decided to join the Deep Bio team because of their commitment to bringing radical changes to the diagnostic field of pathology by applying their state-of-the-art technology towards laboratory automation and diagnostic quality, thereby improving patient care around the world,” said Dr. Bonham. “Pathology is undergoing an incredible digital transformation that will help shape the next generation of precision medicine, Deep Bio is well positioned to become a leader in this space,” he added.
Deep Bio also welcomed a precision medicine expert to its advisory board. Dr. Kamala Maddali (DVM, Ph.D.), the founder and CEO of Health Collaborations, a consulting firm specializing in AI-based precision medicine, is expected to provide insights and support for research collaborations for biomarker discovery in the life sciences sector. Since she started her career at Merck & Co. Dr. Maddali has achieved great accomplishments in her 17 years-plus experience in precision medicine, oncology, and business.
“With its AI-driven insights in pathology, Deep Bio has the unique potential for fostering precise data-driven cancer diagnostics to help better clinical care and precision drug development,” said Dr. Maddali. “I am thrilled to join this promising team and support their great mission to provide total cancer care with the power of AI.”
Sun-Woo Kim, CEO of Deep Bio said “as the digital pathology and AI market continues to grow globally, Deep Bio has continued to build sales channels around the world. With the remarkable advisors now joining Deep Bio, we will strive to establish our presence in the global market and bring innovative products to the industry.”
Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, continues to build its global presence through overseas digital pathology platform providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US. The company also has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, among others.
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr.